SONX earnings analysis
What we found in SONX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q3 2024 showed meaningful operational improvement: revenue was $8,036,000 (down slightly from $8,163,000 in Q3 2023), gross profit rose to $3,310,000 (41.2% margin) from $884,000 (10.8%), and operating loss narrowed to $6,792,000 from $16,565,000 a year earlier. However, the company remains cash constrained — cash + short-term investments totaled $17,284,000 and management discloses substantial doubt about going concern and the need for additional financing. The software business was divested and reported as discontinued operations, producing cash proceeds of $14,208,000 YTD and a gain of $5,703,000.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Gross margin recovery
- Gross profit increased to $3,310,000 in Q3 2024 (41.2% gross margin) from $884,000 in Q3 2023 (10.8%), an improvement of $2,426,000 and ~30.4 percentage points.
- Operating expense reduction
- Total operating expenses fell to $10,102,000 in Q3 2024 from $17,449,000 in Q3 2023, a reduction of $7,347,000, supporting the margin recovery.
- Operating loss materially narrowed
- Operating loss improved to $6,792,000 in Q3 2024 from $16,565,000 in Q3 2023, a quarter-over-quarter improvement of $9,773,000.
- EPS improved vs prior year
- Net loss per share improved to $(15.77) in Q3 2024 from $(37.01) in Q3 2023 (an improvement of $21.24 per share).
- Disposal provided cash and one-time gain
- Proceeds from sale of discontinued operations were $14,208,000 YTD and the sale generated a gain of $5,703,000 (reported in adjustments to cash flow).
- Near-term debt reduced
- Current portion of term loan decreased to $10,800,000 as of September 30, 2024 from $24,900,000 as of December 31, 2023 (reduction of $14,100,000).
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity / going-concern risk
- Cash and cash equivalents were $13,096,000 and short-term investments were $4,188,000 (total $17,284,000) as of September 30, 2024 and the filing discloses 'substantial doubt' about the Company's ability to continue as a going concern.
- Ongoing cash burn
- Net cash used in operating activities for the nine months ended September 30, 2024 was $21,718,000 and net loss before tax for the nine months was $27,171,000, indicating continued negative cash flow.
- Market listing / liquidity compliance risk
- The company was delisted from the NYSE (effective Nov 22, 2023) and received OTC notices: bid price cure period related to $0.10 requirement expired Dec 2, 2024 and a market-cap cure (market cap < $5 million) expires Feb 7, 2025, risking further transfer to OTC Pink.
- Large decline in short-term investments
- Short-term investments decreased from $32,773,000 at December 31, 2023 to $4,188,000 at September 30, 2024, a decline of $28,585,000, materially reducing liquid reserves.
- Outstanding term loan and interest burden
- Aggregate term loan outstanding on the balance sheet is $16,884,000 (current portion $10,800,000 and noncurrent $6,084,000) and the company reported interest expense of $1,010,000 for the quarter and cash interest paid YTD of $2,866,000.
- Concentration on single product offering
- Revenue remains concentrated in the GentleWave product line with continuing operations revenue of $8,036,000 for the quarter, leaving results sensitive to market acceptance and adoption.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-15.77
- Gross margin
- 41.195796%
- Operating margin
- -84.517884%
- Segment
- Product (continuing): Revenue $8,036,000 for Q3 2024 (continuing operations).
- Segment
- Software: Divested (reported as discontinued operations); YTD income from discontinued operations was $5,508,000 and proceeds from sale of discontinued operations were $14,208,000.
What they said about what is next.
No explicit numeric guidance provided. MD&A states management 'expect[s] to continue to incur operating losses for the foreseeable future' and 'The Company will require additional financing' and is 'actively exploring financing options' while pursuing expense reductions. OTC compliance cure deadlines (Dec 2, 2024 and Feb 7, 2025) and the need for additional capital are emphasized; quantitative outlook deferred to financing progress and future disclosures.
The filing reads about the same as the one before it.
What came before.
- 10-Q · August 7, 2024
- Q2 2024 revenue of $8.314M declined 5.1% year-over-year but beat consensus ($7.6M). Gross profit swung to $3.116M (≈37.5% margin) from a gross loss of $(0.485)M a year ago; operating loss narrowed to $(6.687)M from…
- 10-Q · November 8, 2023
- Sonendo reported revenue of $10.406M in Q3 2023, up $0.560M (≈5.7%) versus Q3 2022, with gross profit essentially flat at $2.446M (gross margin ≈23.5%). Operating loss widened modestly to $(16.096)M (op margin ≈…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SONX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever